Evaluation of adjunctive HPV testing by Hybrid Capture II® in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy

BMC Infectious Diseases

John Fox¹  May S Kyi³  Shakir Karim²  Andrea Guyot³ 

[1] Department of Obstetrics and Gynaecology of West Middlesex University Hospital, Twickenham Rd, Isleworth W7 6AF, UK;Department of Pathology of West Middlesex University Hospital and Quest Diagnostics, Twickenham Rd, Isleworth W7 6AF, UK;Department of Microbiology of West Middlesex University Hospital and Quest Diagnostics, Twickenham Rd, Isleworth W7 6AF, UK

关键词: sensitivity and specificity;    Cervical intraepithelial neoplasia;    Human Papilloma Virus;   

Others  :  1177115
DOI  :  10.1186/1471-2334-3-23

 received in 2003-08-01, accepted in 2003-09-25,  发布年份 2003

【 摘 要 】

Background

As a proportion of high grade cervical intraepithelial neoplasia (CIN2/3) are associated with equivocal cervical smears, which show borderline or mild dyskaryosis, follow up with repeat smears, colposcopy and biopsy is required. Since infection with oncogenic Human Papilloma Virus (HR HPV) has been found to be associated with the development of cervical cancer, HRHPV testing appears to be an alternative.

Objective

The present study assesses if HRHPV testing can predict CIN2/3 in women referred for mild dyskaryosis and borderline cytological changes in an health authority with a referral policy to colposcopy after one single mild dyskaryotic Pap smear.

Study design

The HPV DNA Hybrid Capture II (Digene/Abbott, Maidenhead) was evaluated on 110 consenting women with mild dyskaryosis and 23 women with persistent borderline changes, who were referred for colposcopy between May and November 2001. A cost comparison between two referral policies was performed.

Results

CIN2/3 was diagnosed histologically in 30 of 133 women (22%) with minor cytological abnormalities. As the Receiver Operator Characteristics plot suggested a cut-off of 3 pg/ml the HRHPV HCII was evaluated at 3 RLU (relative light units) and at the manufacturer's recommendation of 1 RLU. At both cut-offs sensitivity and negative predictive value were high at 97%. Specificity was low at 37% at a cut-off of 1 pg/ml and 46% at a cut-off of 3 RLU. To remain cost neutral in comparison to immediate colposcopy the costs for one HR HPV HC II must not exceed £34.37 per test at a cut off of 3 pg/ml.

Conclusion

The negative likelihood ratio (NLR) was of good diagnostic value with 0.089 at 1 RLU and 0.072 at 3 RLU, which reduces the post-test probability for CIN2/3 to 2% in this population. Women with minor cytological disorders can be excluded from colposcopy on a negative HR HPV result.

Specificity can be improved by restricting HR HPV testing to women with persistent borderline cytological changes or to women over 30 years.

【 授权许可】

   
2003 Guyot et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Walboomers MM, Jacobs MV, Manos MM, Bosch FX, Kummer A, Shah KV, Snijders PJF, Peto J, Meier CJ, Munoz N: Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [2]Southern SA, Herrington CS: Molecular events in uterine cervical cancer. Sex Transm Infect 1998, 74:101-109.
• [3]Governmental Statistical Service: Cervical Screening Programme, England: 2000–2001. Statistical Bulletin 2001.
• [4]NHSCSP: Guidelines for clinical practice and programme management. NHSCSP publication 1997, 8:12-15.
• [5]Healthcare Financial Management Association: NHS Finance in the UK. Introductory Guide 5th edition. 2000, 56-64.
• [6]Quest Diagnostics: Outcome by 31.3.01 for women recommended for gynaecological referral where the smear was registered during April-June 2000. DH form KC61 Part C
• [7]Colposcopy clinic of West Middlesex University Hospital: Women referred to colposcopy by referral indication. DH form KC65 1.-3. quarter of 2001;Part A
• [8]Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason T, Young LS: Natural history of cervical HPV infection in young women: a longitudinal study. Lancet 2001, 357:1831-1836.
• [9]Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P: HPV testing in primary screening of older women. Br J Cancer 1999, :554-558.
• [10]Wright TC, Lorincz A, Ferris DG, Richart RM, Ferenczy A, Mielzynska I, Borgatta L, et al.: Reflex human papillomavirus deoxyribonucleic testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998, 178:962-966.
• [11]Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, Roth P, Lorincz AT, Gafni A: Comparison of human papillomavirus DNA testing and repeat Papanicolaou testing in women with low-grade cervical cytologic abnormalities: a randomized trial. Can Med Assoc 2000, 163:701-707.
• [12]Rebello G, Hallam N, Smart G, Farquharson D, McCafferty M: Human papilloma virus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ 2001, 322:893-894.
• [13]The Atypical quamous cells of undetermined significance/Low-grade squamous intraepithelial lesions Triage Study (ALTS) group: Human papillomavirus testing for triage of women with with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000, 92:397-402.
• [14]Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA: Identifying women with cervical neoplasia. JAMA 1999, 28:1605-1610.
• [15]Shlay JC, Dunn T, Byers T, Baron A, Douglas JM: Prediction of cervical intraepithelial neoplasia grade 2–3 using risk assessment and human papilloma virus testing in women with atypia on Papanicolaou smear. Obstet Gynecol 2000, 96:410-416.